Vaccines

Delivering a Next-Generation COVID-19 Vaccine for Immunocompromised Patients and Novel Cancer Vaccines

David Dodd; Mark Newman, Ph.D.

GeoVax Inc.

Cell Therapy

Engineering Immune Cells to Realize the Promise of Cancer Cell Therapies

Beau Webber, Ph.D.

Luminary Therapeutics

Immuno-Oncology

Targeted Immune System Activation: A Paradigm Shift in Immuno-oncology

Dan Passeri, M.Sc., J.D.

Cue Biopharma

CAR-T

Enabling Greater Patient Access to CAR-T Cell Therapies with Off-the-Shelf Delivery Solutions

Ryan Larson, Ph.D.

CAR-T and iPSC Platform Technologies

Umoja Biopharma Presents New Preclinical Data on its Integrated In Vivo CAR-T and Engineered iPSC Platform Technologies at the SITC 37th Annual Meeting

Umoja Biopharma

Theranostics

Theranostic Manufacturing Solutions

Muctarr Sesay, Ph.D.

GBI

Cell Therapy

Targeting Cancers by Leveraging the Biology of Gamma Delta T Cells

Bryan Kobel

TC Biopharm

Immuno-Oncology

Tuning the Myeloid Compartment with a Best-in-Class CDMO

Kiren Khanduga; Alicia Levey, Ph.D.

Pionyr Immunotherapeutics

Cell Therapy

Fighting Solid Tumors by Targeting Neoantigens in a Personalized Manner

Mark Shlomchik, M.D., Ph.D.

BlueSphere Bio

Immuno-Oncology

Building Multiple Platforms to Address Difficult-to-Treat Cancers

Derek Hennecke

Inceptor Bio

Oncolytic Viruses

Coverting Viruses into Therapeutic Tools

OncoMyx Therapeutics

Phase I Trial

Anixa Biosciences Announces the Initiation of its Ovarian Cancer CAR-T Phase I Trial at Moffitt Cancer Center

Anixa Biosciences

Anti-Cancer Therapeutic

“Amazing” Nanoparticles from Maize: A Potent and Economical Anti-Cancer Therapeutic

Tokyo University of Science

Immunotherapy Research

Genetically Engineered Dual Receptor T-cells: Double Trouble for Cancer Cells

Juntendo University

Biotech-CDMO Relationship

For mAbs, a Small Biotech Recognizes the Value in Lonza’s Expertise and Track Record

William Ben Jones, Ph.D.

Corvus Pharmaceuticals

Immuno-Oncology

Training the Immune System to Recognize Cancer Cells

Ian B. Walters, M.D., MBA

Portage Biotech, Inc.

Financing

Kahr Announces $46.5 Million Financing to Advance Its Multifunctional Immunotherapeutic Pipeline

KAHR

Cell Therapy

Economically Viable, Same-Day Autologous Cell Therapies

Gregory Frost, Ph.D.; Sid Kerkar, M.D.

EXUMA Biotechnology

Natural Killer T cells

Combating Cancer and Other Diseases with Supercharged NKT Cells

Theresa Deisher, Ph.D.

AVM Biotechnology

Strategic Partnership

Gilead Sciences and Arcus Biosciences Complete Closing of Their 10-Year Partnership to Co-Develop and Co-Commercialize Next-Generation Cancer Immunotherapies

Gilead Sciences